par Maerevoet, Marie 
Référence Revue médicale de Bruxelles, 43, 4, page (306-312)
Publication Publié, 2022-09
Référence Revue médicale de Bruxelles, 43, 4, page (306-312)
Publication Publié, 2022-09
Article révisé par les pairs
| Résumé : | Chronic lymphocytic leukemia (CLL) is the most frequent adult leukemia in the western countries. The diagnosis is based on the blood smear examination and immunophenotyping by flow cytometry of blood lymphocytes. Most of patients are asymptomatic. According to the international Workshop group on CLL (IWCLL) criteria, CLL should only be treated if symptomatic. Despite recent development in therapeutic strategies, the disease remains incurable. The response to upfront and subsequent therapies depends on a variety of factors, including clinical stage, adverse biological prognosis factors and number of prior therapies. Chemoimmunotherapy remains the therapy of choice in upfront therapy for low risk and fit patient and is associated with long duration of remission. New targeted drugs as BTK or BCL2 inhibitor are very effective on overall survival in upfront or in relapse for patients older than 60 years, with comorbidities, and for CLL with adverse biological prognosis factors as TP53 deletion or mutation or unmutated IgVH. The choice of targeted therapy is depending of genetic feature of the CLL and comorbidity profile, comedication and patient's choices. |
